Sept. 15, 2011
/PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) today announced that its 250-ton capacity Jiangchuan Macrolide facility (JCM) is scheduled for the manufacturing environmental assessment in late September.
An environmental impact assessment is an evaluation of the possible positive or negative impact of a project that may have on the environment, including the natural, social and economic aspects. The JCM manufacturing environmental assessment is to examine whether the Azithromycin API plant meets various environmental protection standards during its operation. This is a required procedure for the final Good Manufacturing Practice (GMP) certification approval. The environmental assessment will be conducted by the Environmental Assessment Department of Sichuan Province,
, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and active pharmaceutical ingredients (API). TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of
. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.
For more information about TPI, please visit:
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.